Learn More
Tocris Bioscience™ aTAG 2139

Description
aTAG 2139 is a degrader of MTH1 fusion proteins for use within the aTAG system. Comprises a ligand selective for MTH1, a linker and the cereblon-binding ligand Thalidomide (Cat. No. 0652). Induces highly potent and selective degradation of fusion proteins after a 4 h incubation (DC50 = 0.27 nM; Dmax = 92.1%). Cell-permeable. Suitable for in vitro and in vivo applications.
Negative control aTAG 2139-NEG (Cat. No. 7575) also available.
Mouse DMPK properties are provided in the supplementary file (see below).
MTH1 can be expressed as a fusion with a target protein of interest using genome engineering techniques via CRISPR-mediated locus-specific knock-in. See protocol for more information.
Custom knock-in cell lines for the dTAG and aTAG platforms are available from Bio-Techne .
Specifications
Specifications
| Chemical Name or Material | 6-(6-((4-(2-((2-(2,6-Dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)oxy)acetamido)butyl)carbamoyl)pyridin-3-yl)-N-methyl-4-(phenylamino)quinoline-3-carboxamide |
| CAS | 2387510-81-6 |
| Quantity | 5 mg |
| Target | TAG Degradation Platforms |
| Molecular Formula | C42H38N8O8 |
| Purity | 98% |
By clicking Submit, you acknowledge that you may be contacted by Fisher Scientific in regards to the feedback you have provided in this form. We will not share your information for any other purposes. All contact information provided shall also be maintained in accordance with our Privacy Policy.